MALCOLM BRENNER to Lymphoproliferative Disorders
This is a "connection" page, showing publications MALCOLM BRENNER has written about Lymphoproliferative Disorders.
Connection Strength
0.919
-
Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice. Nat Med. 1998 Nov; 4(11):1253-60.
Score: 0.139
-
EBV specific CTL: a model for immune therapy. Vox Sang. 1998; 74 Suppl 2:497-8.
Score: 0.131
-
Gene-marking and haemopoietic stem-cell transplantation. Blood Rev. 1995 Dec; 9(4):220-5.
Score: 0.113
-
Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. Blood. 2015 Jun 25; 125(26):4103-13.
Score: 0.109
-
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010 Feb 04; 115(5):925-35.
Score: 0.074
-
Overview of gene therapy clinical progress including cancer treatment with gene-modified T cells. Hematology Am Soc Hematol Educ Program. 2009; 675-81.
Score: 0.070
-
Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood. 2004 May 15; 103(10):3979-81.
Score: 0.050
-
Gene transfer and the treatment of haematological malignancy. J Intern Med. 2001 Apr; 249(4):345-58.
Score: 0.041
-
Adoptive immunotherapy of EBV-associated malignancies with EBV-specific cytotoxic T-cell lines. Curr Top Microbiol Immunol. 2001; 258:221-9.
Score: 0.040
-
Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. J Hematother. 1995 Apr; 4(2):73-9.
Score: 0.027
-
Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet. 1995 Jan 07; 345(8941):9-13.
Score: 0.027
-
Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol. 1995 Jan; 89(1):98-103.
Score: 0.027
-
Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts. Hum Gene Ther. 1994 Mar; 5(3):381-97.
Score: 0.025
-
Correction of Duncan's syndrome by allogeneic bone marrow transplantation. Lancet. 1993 Sep 04; 342(8871):587-8.
Score: 0.024
-
T cell therapies. Ernst Schering Found Symp Proc. 2006; (4):69-82.
Score: 0.014
-
Immunotherapy for Epstein-Barr virus-associated cancers. J Natl Cancer Inst Monogr. 1998; (23):89-93.
Score: 0.008